Previous meta-analyses on GLP-1 receptor agonists for obesity treatment have similarly reported high heterogeneity (44), indicating that weight loss responses to these agents are influenced by multiple factors, including baseline BMI, metabolic status, and adherence to treatment. This evidence concerns the gene GLP1R and obesity disorder.